PMID- 28954631
OWN - NLM
STAT- MEDLINE
DCOM- 20180614
LR  - 20240117
IS  - 1532-429X (Electronic)
IS  - 1097-6647 (Print)
IS  - 1097-6647 (Linking)
VI  - 19
IP  - 1
DP  - 2017 Sep 28
TI  - Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 
      subjects.
PG  - 74
LID - 10.1186/s12968-017-0386-y [doi]
LID - 74
AB  - BACKGROUND: Native T1-mapping provides quantitative myocardial tissue 
      characterization for cardiovascular diseases (CVD), without the need for 
      gadolinium. However, its translation into clinical practice is hindered by 
      differences between techniques and the lack of established reference values. We 
      provide typical myocardial T1-ranges for 18 commonly encountered CVDs using a 
      single T1-mapping technique - Shortened Look-Locker Inversion Recovery (ShMOLLI), 
      also used in the large UK Biobank and Hypertrophic Cardiomyopathy Registry study. 
      METHODS: We analyzed 1291 subjects who underwent CMR (1.5-Tesla, MAGNETOM-Avanto, 
      Siemens Healthcare, Erlangen, Germany) between 2009 and 2016, who had a single 
      CVD diagnosis, with mid-ventricular T1-map assessment. A region of interest (ROI) 
      was placed on native T1-maps in the "most-affected myocardium", characterized by 
      the presence of late gadolinium enhancement (LGE), or regional wall motion 
      abnormalities (RWMA) on cines. Another ROI was placed in the "reference 
      myocardium" as far as possible from LGE/RWMA, and in the septum if no focal 
      abnormality was present. To further define normality, we included native T1 of 
      healthy subjects from an existing dataset after sub-endocardial pixel-erosions. 
      RESULTS: Native T1 of patients with normal CMR (938 +/- 21 ms) was similar compared 
      to healthy subjects (941 +/- 23 ms). Across all patient groups (57 +/- 19 yrs., 65% 
      males), focally affected myocardium had significantly different T1 value compared 
      to reference myocardium (all p < 0.001). In the affected myocardium, cardiac 
      amyloidosis (1119 +/- 61 ms) had the highest native T1 compared to normal and all 
      other CVDs, while iron-overload (795 +/- 58 ms) and Anderson-Fabry disease 
      (863 +/- 23 ms) had the lowest native reference T1 (all p < 0.001). Future studies 
      designed to detect the large T1 differences between affected and reference 
      myocardium are estimated to require small sample-sizes (n < 50). However, studies 
      designed to detect the small T1 differences between reference myocardium in CVDs 
      and healthy controls can require several thousand of subjects. CONCLUSIONS: We 
      provide typical T1-ranges for common clinical cardiac conditions in the largest 
      cohort to-date, using ShMOLLI T1-mapping at 1.5 T. Sample-size calculations from 
      this study may be useful for the design of future studies and trials that use 
      T1-mapping as an endpoint.
FAU - Liu, Joanna M
AU  - Liu JM
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Liu, Alexander
AU  - Liu A
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Leal, Joana
AU  - Leal J
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - McMillan, Fiona
AU  - McMillan F
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Francis, Jane
AU  - Francis J
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Greiser, Andreas
AU  - Greiser A
AD  - Siemens Healthineers, Erlangen, Germany.
FAU - Rider, Oliver J
AU  - Rider OJ
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Myerson, Saul
AU  - Myerson S
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Neubauer, Stefan
AU  - Neubauer S
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Ferreira, Vanessa M
AU  - Ferreira VM
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK.
FAU - Piechnik, Stefan K
AU  - Piechnik SK
AD  - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of 
      Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
      Oxford, OX3 9DU, UK. Stefan.piechnik@cardiov.ox.ac.uk.
LA  - eng
GR  - FS/15/11/31233/BHF_/British Heart Foundation/United Kingdom
GR  - MC_QA137853/MRC_/Medical Research Council/United Kingdom
GR  - PG/15/71/31731/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
DEP - 20170928
PL  - England
TA  - J Cardiovasc Magn Reson
JT  - Journal of cardiovascular magnetic resonance : official journal of the Society 
      for Cardiovascular Magnetic Resonance
JID - 9815616
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Heart/anatomy & histology/diagnostic imaging
MH  - Heart Diseases/*diagnostic imaging
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
PMC - PMC5618724
OTO - NOTNLM
OT  - Affected myocardium
OT  - Cardiac magnetic resonance
OT  - Late gadolinium enhancement
OT  - Reference myocardium
OT  - ShMOLLI
OT  - T1-Mapping
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study received favourable 
      opinions from National Health Service (NHS) Health Research Authority, Oxford 
      University Hospitals NHS Foundation Trust Research and Development Department and 
      the Oxford University Clinical Trials & Research Governance. Written consent was 
      gained from all study subjects. CONSENT FOR PUBLICATION: Not applicable. 
      COMPETING INTERESTS: SKP has patent authorship rights for U.S. patent 9,285,446 
      B2. Systems and methods for shortened look locker inversion recovery (Sh-MOLLI) 
      cardiac gated mapping of T1. Granted March 15, 2016. IP is managed by Oxford 
      University Innovations; the licence exclusively transferred to Siemens 
      Healthcare. All other authors have no relationships relevant to the contents of 
      this paper to disclose. PUBLISHER'S NOTE: Springer Nature remains neutral with 
      regard to jurisdictional claims in published maps and institutional affiliations.
EDAT- 2017/09/29 06:00
MHDA- 2018/06/15 06:00
PMCR- 2017/09/28
CRDT- 2017/09/29 06:00
PHST- 2017/03/31 00:00 [received]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/09/29 06:00 [entrez]
PHST- 2017/09/29 06:00 [pubmed]
PHST- 2018/06/15 06:00 [medline]
PHST- 2017/09/28 00:00 [pmc-release]
AID - S1097-6647(23)01108-0 [pii]
AID - 386 [pii]
AID - 10.1186/s12968-017-0386-y [doi]
PST - epublish
SO  - J Cardiovasc Magn Reson. 2017 Sep 28;19(1):74. doi: 10.1186/s12968-017-0386-y.